The Expert Council of the European Medicines Agency recommended that regulatory authorities approve the preparation of galcanesumab, developed by the American company Eli Lilly for the treatment of a migraine. Clinical studies show that the drug is effective in reducing the number of attacks of a headache. Galceanumab is a monoclonal antibody specific for the…